Arava Label Strengthened Following Reports Of Interstitial Lung Disease

Sanofi-Aventis adds stronger warnings for the rheumatoid arthritis drug following post-marketing reports of interstitial lung disease in Japan. Patients should notify their physician and may need to discontinue therapy if pulmonary symptoms develop. Updated labeling also includes geriatric use information.